Table 4 Results of the univariate analysis
Parameter | Number of patients | MDBFT (months) | 95% confidence interval | p value |
|---|---|---|---|---|
No. of metastases | Â | Â | Â | 0.003 |
1 | 86 (65.2%) | 54 | -- | Â |
> 1 | 46 (34.8%) | 8 | 2.0-14.1 | Â |
Total target volume (cc) | Â | Â | Â | 0.021 |
> 6 | 50 (37.9%) | 10 | 4.7-15.3 | Â |
≤ 6 | 82 (62.1%) | 21 | 11.8-30.2 |  |
Extracranial disease | Â | Â | Â | 0.003 |
progressive | 91 (68.9%) | 11 | 6.3-15.7 | Â |
absent or controlled | 41 (31.1%) | Not reach | -- | Â |
IT(months) | Â | Â | Â | 0.011 |
≥ 60 | 20 (15.2%) | Not reach | -- |  |
< 60 | 112 (84.8%) | 12 | 7.6-16.5 | Â |
KPS score | Â | Â | Â | 0.012 |
KPS = 70 | 45 (34.1%) | 10 | 3.3-16.7 | Â |
KPS ≠70 | 87 (65.9%) | 21 | 9.5-32.5 |  |
Histologic characteristics | Â | Â | Â | 0.762 |
Melanoma | 5 (3.8%) | 18 | 0-41.4 | Â |
Others | 127 (96.2) | 15 | 7.7-23.3 | Â |
Risk factor scores | Â | Â | Â | < 0.001 |
0-1 | 27 (20.5%) | Not reach | -- | Â |
2-3 | 92 (69.7%) | 13 | 8.4-17.6 | Â |
4 | 13 (9.8%) | 3 | 2.0-4.0 | Â |